Journal
NEUROMUSCULAR DISORDERS
Volume 18, Issue 5, Pages 410-412Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.nmd.2008.03.005
Keywords
myopathy; statin; orlistat; coenzyme Q(10); weight loss; CK; creatine phosphokinase
Categories
Ask authors/readers for more resources
The pathogenesis of myopathy due to HMG-CoA reductase inhibitors is not entirely clear but the existence of myopathy due to other lipid-lowering medications suggests it is mediated through effects on lipid metabolism. We describe a patient who developed a myopathy after 27 months of ingestion of orlistat that slowly improved after discontinuation of the drug. Orlistat may have caused this myopathy through depletion of a critical nutrient or through some as of yet undefined mechanism. (c) 2008 Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available